Sorry lori but with only tomorrow to trade before Thanksgiving, I'm going to have say it's quite a lot to ask when we haven't closed that high for a heck of a long time.....BUT....color me thrilled IF it does happen!! Hope you and everyone here long XXII enjoys their Thanksgiving!!
It comes down to product variation. Xxii holds the key. Variation in a product that generates 700 billion dollars world wide. Only a quarter of a PERCENTAGE point makes this a $15 a share company. Product variation with a patent to boot...
Sounds expensive despite their claims to the contrary. I stopped believing in this company when they were unable to demonstrate a profit on all of the sales they have made. What is the point of selling product if all it does is accelerate losses? Everyone seems to justify the valuation of this company based on the patents they hold. However, they are just licensing the patents and these can expire with no benefit to XXII if they cannot monetize them. Despite the assertion by management that they would not want to dilute shares with another offering, I don't see how they can keep going if they don't. They are burning cash at an ever increasing pace and are fragmented on the path forward. They can't make up their mind if they want to spend their money selling cigarettes or developing new biotech. If they had been able to show any promise of actual profits from the sale of Red Sun and Magic, then I would have stayed on board. As it stands though, I expect there to be another significant hit to the share price in the near future before this has any chance of getting significantly better.
Sentiment: Strong Sell
22nd Century Group to Open Laboratories to Lower Costs of Research and Speed Development of Important New Products
22nd Century Group, Inc. (AMEX:XXII)
Intraday Stock Chart
Today : Tuesday 24 November 2015
Click Here for more 22nd Century Group, Inc. Charts.
Company to Present at LD Micro Investor Conference on December 2nd
22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, announced today that it will open specialized laboratories in Western New York dedicated to new scientific research at substantially lower costs than sponsored research projects at third-party universities. Paul J. Rushton, Ph.D., the Company’s recently appointed Cambridge and Max Planck Institute-educated Vice President of Plant Biotechnology, will lead this new scientific initiative. The new laboratories will accelerate the development of new nicotine-free tobacco varieties as well as the invention of important tobacco products.
Dr. Rushton explained, “This is a very exciting time for our Company. Our new laboratories will provide 22nd Century with the in-house capabilities to rapidly expand our genomics-based research and to accelerate commercialization of our technologies.”
“The new 22nd Century laboratories will enable us to continue to grow our patent portfolio – but at substantially reduced costs,” explained Henry Sicignano III, President and CEO of 22nd Century Group. “What’s more, using our own labs will enable us to own, outright, the patents that we develop rather than having to license them from sponsored third-party researchers.”
In other news, 22nd Century announced today that the Company will present at the LD Micro Invitational Conference at the Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, on Wednesday, December 2, 2015 at 1:30 p.m. PST.
The LD Micro investor conference focuses on revealing to qualified investors promising, undervalued companies in the micro-cap space. Mr. Sicignano will provide attendees with a formal update, business overview, and highlights of recent 22nd Century Group activity. In addition, Mr. Sicignano will be available for one-on-one meetings at the conference.
To arrange a one-on-one meeting with 22nd Century, please contact Andrew Haag at email@example.com or call 866-976-4784.
About 22nd Century Group, Inc.
22nd Century Group is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission is to reduce the harm caused by smoking. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications around the world. The Company’s strong IP position led to a licensing agreement with British American Tobacco (“BAT”), the world’s second largest tobacco company. Visit www.xxiicentury.com for more information.
Well, we broke $1.45. Almost closed. Above $1.50. Should be today. Then go for $1.60 Wednesday.
moving slowly up...with FDA/USDA as research partners, my guess is we're in for good news by end of year. just my opinion, however.
That's a lot to ask, but I'd feel more likely that level may be reached by the end of the year. Also a strong January Effect would be appreciated this coming year since it was skipped in 2015.
It would seem to bode well for the pps Ian. I will say, XXII has been one of the MOST volatile stocks I've been in for awhile in recent trading. The high of $1.75 and low of $1.12 in maybe a 2-3 day span gives us an idea of how quickly and far this stock can move given some good news!! GL to us all...